Financial Performance - The company's total adjusted EBITDA for 3Q25 was $610.3 million[6], compared to $538.9 million in 3Q24[6] - For the nine months ended September 30, 2025, the adjusted net income attributable to Labcorp Holdings Inc was $1038.3 million, compared to $939.9 million for the same period in 2024[22] - The adjusted earnings per share for the three months ended September 30, 2025, was $4.18, compared to $3.50 for the same period in 2024[23] Revenue Analysis - Enterprise revenues, as reported, for 3Q25 were $3,564 million, an increase of 8.6% year-over-year[8] - Diagnostics Laboratories revenues, as reported, for 3Q25 were $2,770 million, an increase of 8.5% year-over-year[8] - Biopharma Laboratory Services revenues, as reported, for 3Q25 were $799 million, an increase of 8.3% year-over-year[8] - The company's revenue growth in Diagnostics Laboratories for 3Q25 was primarily driven by volume (4.7%) and price/mix (3.7%)[15] Outlook for 2025 - The company updated its 2025 revenue guidance for Labcorp Enterprise to a range of $13.97 billion to $14.05 billion, representing a growth of 7.4% to 8.0% versus 2024 results[18] - The company updated its 2025 adjusted EPS guidance to a range of $16.15 to $16.50, representing a growth of 10.8% to 13.2% versus 2024 results[18] Biopharma Laboratory Services - The trailing twelve-month net orders for Biopharma Laboratory Services ending September 30, 2025, were $3.34 billion, with a net book-to-bill ratio of 1.09x[17]

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the effect of the holding company reorganization on the company's business generally; (ii) the failure to receive tax-free treatment with respect to the spin-off of the company's Clinical Development and Commercialization Services business, now Fortrea Holdings Inc. for U.S. federal income purposes; (iii) the impact of spin-off rela ...